Summary
Clinical Trial Disclosure (CTD) is a compliance requirement mandated by various national laws and policies, and is at the heart of a paradigm shift towards greater trial transparency. CTD consists of registering protocol-related information and posting clinical trial study results on publicly-accessible databases. By disclosing information, sponsors provide a record of a study’s design, objectives, and results, and demonstrate scientific integrity to regulators, scientific journals, and trial participants.
Trial disclosure requirements exist for most trials in patients. The US and EU governments maintain registries where protocol information is submitted, maintained, and updated from a study’s initial approval through study completion. Many other countries maintain local registries, requiring oversight for ensuring global harmonization and compliance. The introduction of data sharing and anonymization, now becoming a focus of scientific journals, patient advocacy groups, and other organizations, further broadens the transparency landscape, and reinforces the need for sponsors to proactively implement transparency policies.
Register to download
Clinical Trial Disclosure - Requirements & Strategy Considerations within Clinical Trial Transparency
You may also be interested in:

Plain Language Summaries - Keeping the End in Mind: Key Considerations for Creating Plain Language Summaries
Plain language summaries (PLS), also known as lay summaries and trial results summaries, educate participants and the public about clinical trial…

Data Sharing & Anonymization - Current Overview of Data Sharing within Clinical Trial Transparency
Clinical trial transparency has emerged in recent years as a key function within pharmaceutical and academic organizations. Although trial…

5 Ways Regulatory Strategists Increase Your Chance of Product Approval
There’s an old adage: “Plan your work, then work your plan.” This statement is never more valid than in the area of regulatory strategy. Regulatory…